Rheumatology for the GP

Slides:



Advertisements
Similar presentations
RHEUMATOID ARTHRITIS RA Inson lou. Epidemiology Symptoms signs Labs Diagnosis Treatment.
Advertisements

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.
NSAIDs 1 st line of therapy in the medical management of RA.
Rheumatoid Arthritis Systemic chronic inflammatory disease
Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,
RHEUMATOID ARTHRITIS VS OSTEOARTHRITIS Anusha Reddy FY1 General Surgery (UHCW) 25 th Nov 2013.
Anti-Inflammatory & Immunosuppressive Drugs 2
INPATIENT’S RHEUMATOLOGICAL PROBLEMS Dr Tanya Potter Consultant Rheumatologist UHCW.
Dr. Fahim Khan MBBS,MD,MRCP(UK),FRCPLondon,FRCP Edin, FACP Rheum CONSULTANT RHEUMATOLOGIST Aut Even Hospital, Kilkenny Whitfield Clinic Waterford,The St.
Achy shoulders and a very high CRP Sarah Tansley Rheumatology, Clinical Fellow.
History of PMR 1888 First described as senile rheumatic gout (Bruce) 1936Secondary fibrositis 1945Periarthrosis humeroscapular 1946Peri-extra-articular.
IMPROVING EARLY DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS Michael Lockwood, MD, FACP, FACR Rheumatology Indiana University Health Arnett.
AM Report Cat Hathaway 3/16/2010.  Proximal myalgia of the hip and shoulder girdles associated with morning stiffness (at least 1 hour)  Etiology is.
Management of Rheumatoid arthritis, Osteoarthritis & Gout Dr. Eoin Casey MD FRCPI, FRCP.
Diagnosing inflammatory arthritis
Value of inflammatory markers Useful for diagnosis of inflammatory vs non inflammatory conditions Remember NON-SPECIFIC, increased in infection, inflammation,
DR.IBTISAM JALI MEDICAL DEMONSTRATOR
The Child With Joint Pain Diagnostic Clues
Tena Trbojević Mentor: A. Žmegač Horvat
Drugs used in joint diseases
All About Rheumatoid Arthritis
Hot Topics in Rheumatology Prof. MG Molloy. Overview Rheumatoid Arthritis Psoriatic Arthritis Vasculitides: SLE Osteoarthritis Osteoporosis.
New Pharmacologic Treatment Options for Managing Rheumatoid Arthritis Devra Dang, Pharm.D. Department of Pharmacy National Institutes of Health.
Treatment of Rheumatoid Arthritis Then and Now
Rheumatology teaching Pilot 4 sessions Pilot 4 sessions Consultant Rheumatologist/student presentation Consultant Rheumatologist/student presentation Based.
Polyarthralgia Tanya Potter Consultant Rheumatologist UHCW.
Disease –Modifying Antirheumatic Drugs ( DMARDs) Slow Acting Anti-inflammatory Drugs.
Interventions for Clients with Connective Tissue Disease and Other Types of Arthritis.
Rheumatoid Arthritis Anila Malik GPVTS. Aims To cover the following: What is RA? Diagnostic criteria and clinical features Rheumatoid Factor Investigations.
Juvenile Rheumatoid Arthritis.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.
Polymyalgia Rheumatica A micro-teach of BSR & BHPR guidelines
Case #13 Ellen Marie de los Reyes March 15, 2007.
Rheumatoid Arthritis (RA) By: Leon Richardson Period
Interventions for Clients with Connective Tissue Disease and Other Types of Arthritis.
Adult Medical-Surgical Nursing Musculo-skeletal Module: Rheumatoid Arthritis.
Rheumatology teaching session GP ST2 year 8/9/10.
Skeletal System Disorders. A. Arthritis Describes over 100 different inflammatory or degenerative diseases.
Approach to the Treatment of RA Try to figure out ‘what type’ of Rheumatoid Arthritis the patient has This is not a uniform disease Young, Sero-positive.
Locomotor system Dr : BASMA EL-HABBASH Rheumatology unit Tripoli Medical Center.
Rheumatoid Arthritis.
Juvenile Rheumatoid Arthritis. Sakharova Inna. Ye., MD, Univ. assistant.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
Elsevier items and derived items © 2006 by Elsevier Inc. Interventions for Clients with Connective Tissue Disease and Other Types of Arthritis.
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
Disease modified Anti-rheumatic drugs ( DMARD)
Modern Therapeutics in Rheumatic Diseases Alistair Duncan (Clinical Pharmacist) Lynn Sinclair (Rheumatology Nurse) The Robert Gordon University Non Medical.
Rheumatoid Arthritis Christine Aranyi and Rebecca Boon State university of new york institute of technology Pathophysiolog y Rheumatoid Arthritis (RA)
Failure of 2 standard DMARDs including MTX for 6 months DAS28 > 5.1 on 2 occasions 1 month apart TOLERANT MTX Choose most appropriate agent and if no clear.
Rheumatoid arthritis (RA).  Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally.
Introduction to collagen-vascular diseases. Definition: Rheumatologic (or Rheumatic) Disease: diseases characterized by pain and inflammation in joints.
Identifying Early Inflammatory Arthritis
BIOLOGICS IN RHEUMATIC DISEASES – UPDATE 2017
Crystalopathies Joanna Zalewska.
DMARDs Disease-Modifying Anti rheumatic Drugs
Rheumatoid Arthritis: Management and New Therapies
Treatment Goal of treatment reduce inflammation and pain
3e Initiative 2009 How to investigate and follow-up Undifferentiated Peripheral Inflammatory Arthritis? Case 3 1.
Managing Rheumatoid arthritis
55 Rheumatoid arthritis.
54 Osteoarthritis.
Drug Therapy of Rheumatoid Arthritis
PMG Patient Information Evening
What’s new in my specialty- Rheumatoid Arthritis
Musculoskeletal Pharmacology
L Alvarez 2018 Adjuncts to Steroid Treatment
Rheumatoid Arthiritis
Polymyalgia and Giant Cell Arteritis
Nat. Rev. Rheumatol. doi: /nrrheum
Presentation transcript:

Rheumatology for the GP Abid Yusuf ST5 Rheumatology & GIM

Plan What we do The rheumatological history Key conditions Drugs Referrals Questions

History Inflammatory arthritis Connective Tissue Disease Early morning stiffness Joint swelling Distribution Rashes IBD Preceding infection Iritis Character of pain Connective Tissue Disease Raynaud’s Mouth ulcers Dry mouth/eyes Myalgia Tight skin Fatigue

Gout Acute Chronic Investigations NSAIDs Colchicine Steroids 4 weekly follow up Allopurinol Febuxostat Etc Investigations U&Es Uric acid X ray affected areas Diet

Giant Cell Arteritis No Yes Typical History Includes Eye symptoms? Admit IV Methylprednisolone for 3 days Ophthalmology referral Vascular surgery referral for TAB Consider Aspirin 75mg Consider bone protection Refer to Rheumatology Prednisolone 40-60mg Orally +Proton Pump Inhibitor Consider Aspirin 75mg Consider bone protection Refer to Rheumatology

PMR Onset Shoulder and hip girdles Myalgia Key manoeuvres Constitutional symptoms Investigations FBC U&E CK RF, Anti-CCP Ig’s Serum electrophoresis CXR Management Start prednisolone 15mg PO OD Should have excellent response within 24-48 hours Consider bone protection

Early Inflammatory Arthritis Swollen tender joints Back pain Inflammatory Mechanical Stiff Fatigue Investigations FBC U&E CRP, ESR Uric acid RF, Anti-CCP B27 (if SpA features) X ray hands and feet ?erosions Treatment Avoid steroids if possible NSAIDs Refer early!

Vasculitis Purpuric rash Preceding infection ENT Haemoptysis Asthma Neuropathy Inflammatory eye disease Always do urine dip Investigations URINE DIP Protein:Creatinine Ratio, red cell casts FBC U&E LFT ANA, dsDNA ANCA RF CXR

Chronic pain/Fibromyalgia Generalised pain Unrefreshing sleep Low mood IBS Investigations Beighton score FBC, U&E, Ca, Vit D TFT 9am cortisol CK ANA, dsDNA Myeloma screen in older people Interventions Believe them Graded exercises CBT Pain management Pacing

Beighton Score

Antibodies If inflammatory arthropathy suspected Rheumatoid factor Anti-CCP antibodies If connective tissue disease suspected ANA ENA dsDNA If Vasculitis suspected ANCA ANA + dsDNA Rheumatoid Factor/Cryoglobulins Hepatitis Screen

Targeted synthetic DMARD Types of DMARD Biologic DMARD Anti-TNFa Infliximab Etanercept Adalimumab Golimumab Certolizumab Anti-IL6 Tocilizumab Sarilumab Anti-CD20 Rituximab Targeted synthetic DMARD JAK inhibitors Baricitinib Tafacitinib Nonbiologic DMARD Methotrexate Sulfasalazine Leflunomide Hydroxychloroquine Azathioprine Mycophenolate Mofetil

Drug monitoring Local set up FBC, LFT Blood testing schedule when initiating DMARD 2 weekly for 6 weeks Monthly for 3 months 3 monthly

Referrals

Questions?